<DOC>
	<DOCNO>NCT02528396</DOCNO>
	<brief_summary>This double-blind , randomise , control , two period crossover phase Ib trial use individualized standard meal fix nutrient ratio subject type 1 diabetes mellitus investigate postprandial blood glucose control BioChaperone insulin lispro compare Humalog® . The assessment conduct period multiple daily dose administration 14 day . The meal tolerance test perform day 1-3 day 14 period . Furthermore study aim investigate Post-prandial glucose ( PPG ) profile BioChaperone insulin lispro Humalog® inject various injection meal interval ( -15min , 0 minute , +15 minute ) . Each subject randomise sequence two treatment , either BioChaperone insulin lispro-Humalog® Humalog®-Biochaperone insulin lispro , three different sequence injection-meal interval . A blinded patient continuous monitoring glucose ( CGM ) perform 14 day treatment period .</brief_summary>
	<brief_title>To Investigate Efficacy Safety Individualized Doses BioChaperone Insulin Lispro Comparison Humalog® U-100 Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) ≥ 12 month Treated multiple daily insulin injection ( pump user ) ≥ 12 month Current total daily insulin treatment &lt; 1.2 ( I ) U/kg/day Body mass index ( BMI ) 18.528.0 kg/m² ( inclusive ) HbA1c ( N ( 1deoxy ) fructosylhaemoglobin ) ≤ 9.0 % local laboratory analysis Fasting Cpeptide ≤ 0.30 nmol/L Known suspected hypersensitivity trial product relate product Type 2 diabetes mellitus Patients use continuous subcutaneous insulin infusion ( CSII ) Previous participation trial . Participation define randomise The receipt investigational product within 3 month prior trial Clinically significant abnormal haematology , biochemistry , lipid , urinalysis screening test , judge Investigator consider underlying disease Presence clinically significant acute gastrointestinal symptom ( e.g . nausea , vomit , heartburn diarrhoea ) , judge Investigator Known slow gastric empty gastrointestinal surgery opinion investigator might change gastrointestinal motility food absorption Unusual meal habit special diet requirement unwillingness eat food provide trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>